Nature Reviews Drug Discovery

Article	Citations
Vaccine exposes tumours to immune cell attack	1579
A specific biomarker for insoluble tau	965
Targeting tumour-associated bacteria	738
A new path to targeted protein degradation?	720
Neutralizing Zika virus	629
The improving benefit–risk balance of phase I cancer trials	624
Tumour cells get a dendritic cell makeover	562
Glucose-sensitive insulin protects against hypoglycaemia	534
Promoting tissue repair after heart attack	449
Hypoimmune iPSCs escape immune detection	438
Lipid nanoparticle ferries therapeutic mRNA to the placenta	437
New antibiotic for urinary tract infections nabs FDA approval	414
First-in-class IL-15 receptor agonist nabs FDA approval for bladder cancer	413
FDA new drug approvals in Q1 2023	397
Apolipoprotein L2 inhibitor mitigates fibrosis	396
FDA approves second TTR stabilizer for cardiac amyloidosis	394
Targeting drug-resistant glioblastoma	383
Degrading cell-free DNA to prevent recurrent stroke	379
Target identification and assessment in the era of AI	356
AI serves up target and inhibitor for lung fibrosis	317
2022 FDA approvals	316
FDA approves a c-MET-targeted ADC for lung cancer	305
Small-molecule discovery through DNA-encoded libraries	293
Targeting the Hippo pathway in cancer	279
Chemical engineering of CRISPR–Cas systems for therapeutic application	257

BRAF plus MEK inhibitor combo secures tumour-agnostic FDA approval	256
Anti-tau antibody stumbles in phase II Alzheimer trial	256
mRNA vaccines for infectious diseases — advances, challenges and opportunities	234
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets	231
Increasing the potency of T cell therapies	225
Pushing both sides of the drug pricing aisle	216
Small molecule improves muscle function in myasthenia gravis	216
TCR-engineered T cells get personal	204
R&D re-balancing act	202
Inhibiting ASGR1 boosts cholesterol removal	201
2025’s FDA approvals by regulatory designations	195
Rewired proteostasis in KRAS inhibitor resistance	192
An allosteric site on cereblon	185
Mimicking the health benefits of exercise	182
FDA approves first DLL3 × CD3 bispecific T-cell engager for lung cancer	182
Host-directed antiviral blocks SARS-CoV-2 entry	181
A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics	178
FDA approves anti-CD3 antibody to delay type 1 diabetes onset	166
Base editors hit the clinic	161
Author Correction: Identification of neoantigens for individualized therapeutic cancer vaccines	152
Combating antimicrobial resistance in malaria, HIV and tuberculosis	148
A peptide-guided strategy for kinase activation	146
Amylin takes another shot at the obesity prize	146
FDA new drug approvals in Q2 2023	145
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders	145
A renaissance in targeting the PI3K/AKT/mTOR pathway	140
The significance of blockbusters in the pharmaceutical industry	139
Roads and detours for CAR T cell therapy in autoimmune diseases	135
The antibody–drug conjugate landscape	135
The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap	130
Antibody–drug conjugates come of age in oncology	130
Multi-TACs target solid tumours	125
Immunology on the brain	119
Reducing IL-2 toxicity	118
Gut metabolite mediates nerve repair	118
Agonist antibody lowers blood pressure	115
Monkeypox mRNA vaccine protects mice and macaques	109
FDA approves J&J’s FcRn blocker for generalized myasthenia gravis	109
Neglected tropical diseases go global	109
FDA approves first-in-class TRPM8 ion channel agonist for dry eye disease	108
GSK buys Affinivax for up to $3.3 billion, bolstering its vaccine pipeline	107
Oral IL-23-blocking peptide racks up phase III wins in inflammatory disease	105
Targeting the ECM in melanoma	99
Redirecting mast cells for antigen-specific cancer immunotherapy	98
Designing G-protein-selective allosteric modulators	95
Ribosome inhibitor combats bacterial drug resistance	95
LRRK2-targeted Parkinson disease drug advances into phase III	93
The European Innovation Network as a hub for medicines innovation in Europe	91
Anti-IL-11 antibody shows anti-ageing properties	89
Realizing the potential of agonistic antibody immunotherapy	86

Frameworks for transformational breakthroughs in RNA-based medicines	81
Avidity in antibody effector functions and biotherapeutic drug design	81
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies	81
Targeting claudins in cancer	77
Engineered parasite delivers proteins to the brain	75
Engineering a compact genome-editing tool	74
Delivering genome editing tools to primary cells	73
Upcoming market catalysts in Q4 2023	71
The non-small-cell lung cancer drug market	70
FDA advisory committee votes for approval of first microbiome-based drug, despite data problems	69
Broader horizons for cereblon glue degraders	68
Accelerating precision oncology by converging pragmatic trials and real-world evidence	63
Publisher Correction: Roflumilast	62
RNA structure guides antiviral ASO design	61
FDA approves a rare novel–novel oncology combination that pairs a first-in-class FAK inhibitor with a MEK–RAF glue inhibitor	60
Betting on β-catenin inhibitors in oncology	60
Covalent inhibitor engages oncogenic AKT kinase	60
Investigating the origins of recent pharmaceutical innovation	58
MYC in cancer: from undruggable target to clinical trials	57
A rush of CRISPR to the lungs	56
AAV-based in vivo gene therapy for neurological disorders	55
Promoting efferocytosis heals diabetic wounds	54
Targeting protein disorder: the next hurdle in drug discovery	53
Trends in the development of cellular and gene therapy in China	53
Three-step cures for autoimmune diseases?	50
A bacteria-derived oral tumour vaccine	49
V-ATPase inhibitor targets Ras-mutant cancers	48
Upcoming market catalysts in Q4 2024	47
Designing novel macrocyclic drugs	47
Can large, simple trials bring drug developers back to common diseases?	46
Halda secures biggest induced-proximity deal yet, with J&J’s US$3 billion buy out	45
Calico, Alphabet’s anti-ageing play, goes it alone	45
Towards a broad-spectrum antiviral agent	45
De novo design of macrocycles	44
Understanding LAG3 immune checkpoint function	44
FDA approves cell-sheet-based gene therapy for severe skin disease	44
Microbial ‘dark matter’ yields new antibiotic	41
Neurotensin receptor modulator safely tackles pain	39
Glue-based KRAS inhibitors make their debut cancer trial mark	39
Cartilage regeneration for osteoarthritis	39
The case for cell-penetrating peptides	38
Analysis of China-to-West pharmaceutical licensing deals in 2024	38
Hinge modifier approach opens door to drugging HECT E3 ligases	36
RNA delivery heats up cold tumours	35
A new drug target for NRAS(Q61) mutant-expressing cancers	35
FDA approves an HDAC inhibitor for Duchenne muscular dystrophy	34
PPAR agonists provide new treatment options for inflammatory liver disease	34
The evolution of the obesity drug market	34
Novel strategies to manage CAR-T cell toxicity	33
RNA chemistry and therapeutics	32
2023 FDA approvals: unprecedented volume at moderate value	32
Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics	30
The 60-year evolution of lipid nanoparticles for nucleic acid delivery	30
Designing closure-stabilizing integrin inhibitors	29
Transcription reprogramming to enhance CAR-T cell function	29
Synthetic cytokine circuit targets solid tumours	29
A step closer to in vivo editing of haematopoietic stem cells	28
FDA approves 21-valent pneumococcal vaccine	28
PD1 × VEGF blocking bispecifics for cancer draw big backing	27
Designing insulin receptor agonists	27
Antisense and CRISPR-based drugs build cases for better hereditary angioedema treatments	26
FDA approves first factor XIIa inhibitor, for hereditary angioedema	25
Improving efficacy of ASO therapy in SMA	25
CAR T cells take to the airways	25
Rebalancing cardiolipin biosynthesis to treat cardiomyopathy	25
FDA approves PI3Kα inhibitor that does double duty as a degrader	25
Enhancing CAR-T cell efficacy through IFN ablation	24
Genome-editing medicinal products: the EMA perspective	23
Novel schizophrenia therapy filed for FDA approval	23
Top product forecasts for 2025	23
Safety considerations for cereblon-recruiting targeted protein degraders	23
A faster route to antidepressant activity	23
Sequential immunotherapy: towards cures for autoimmunity	22
Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs	22
Quantitative systems toxicology: modelling to mechanistically understand and predict drug safety	22
Unmet needs in vaccine development	22
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)	22
Targeting galectin-driven regulatory circuits in cancer and fibrosis	22
In vivo CAR T cells move into clinical trials	22
Drugging the efferocytosis process: concepts and opportunities	21

The aryl hydrocarbon receptor: a rehabilitated target for therapeutic immune modulation	21
Understanding the effects of antibiotic combinations	21
RNAi-based drug design: considerations and future directions	21
Acyl-lysine reader inhibitor blocks AML progression	21
Immuno-oncology clinical trials take a turn beyond PD1/PDL1 inhibitors	21
Synthesizing portimines	21
Brain glucose mediates amphotericin B tolerance	20
Stalled molecular motor inhibits tumour growth	20
Building on the momentum of N-of-1 base editor therapies for rare diseases	20
Epigenetic editor silences prion protein	20
Open-science drug discovery for COVID-19	20
ASO targets DNA repair protein to combat Huntington disease	20
Bacteria tag tumours for CAR-T cell attack	20
Treating cannabis use disorder	20
Lilly buys Verve and its in vivo gene editors for up to US$1.3 billion	19
CRISPR activation tackles neurodevelopmental disorders	19
Novel drug candidates for hard-to-treat hypertension vie for blockbuster positioning	19
Neurons give metastatic cells a push	19
Insights into new approach methodology innovation: an EMA perspective	18
In vivo CAR T cells gain traction, with AbbVie’s US$2.1 billion acquisition of Capstan Therapeutics	18
FDA approves GLP-1 pill for obesity	18
Dose-finding and optimization in drug development for rare diseases	17
The KRAS crowd targets its next cancer mutations	17
Trends in the drug target landscape for autoimmune diseases	17
Trends in the landscape of clinical trials of innovative drugs in China since 2015	17
Bluebird Bio’s cut-price sale highlights challenges for gene therapy field	16
FDA approves first GPRC5D × CD3-targeted bispecific for multiple myeloma	16
Dual-vector gene therapy for hearing loss secures first FDA approval	16
Kinase inhibitors trigger target degradation	16
Thinking outside the box: non-canonical targets in multiple sclerosis	15
A guide to effective drug development through nonprofit models	15
Advanced technologies for the development of infectious disease vaccines	15
Trustworthy AI for safe medicines	15
Alnylam scores big pharma support for angiotensinogen silencer	15
FDA releases tissue-agnostic cancer drug draft guidance	14
Understanding immunomodulatory antibody agonism	14
Soluble Notch agonists drive T cell production	14
Gene editing addresses antithrombin deficiency	14
Understanding sphingosine-1-phosphate transport	14
Ramping up mitochondrial DNA replication	14
A new antibiotic for A. baumannii	14
Setting GPCRs free	14
FDA approves first claudin-18.2-targeted antibody for gastric cancer	13
FDA approves first gene therapy for Duchenne muscular dystrophy, despite internal objections	13
FDA approves first two drugs for rare Niemann–Pick disease	13
The renal cell carcinoma drug market	13
Phosphatase inhibitor drives anticancer immune responses	12
Neutrophil-targeting drug seeks first approval in an inflammatory lung disease	12
FDA approves first chikungunya vaccine	12
The ovarian cancer drug market	12
Upcoming market catalysts in Q3 2023	12
Targeting ALDH1B1 in colorectal cancer	12
Targeting cytokine networks in neuroinflammatory diseases	11
Treatment of chronic obstructive pulmonary disease: current pipeline and new opportunities	11
Antibody drug conjugate combats inflammation	11
Macrophages as tools and targets in cancer therapy	11
Two-pronged approach for macular degeneration	11
Targeting expanded trinucleotide repeats	11
Membrane transporters in drug development and as determinants of precision medicine	11
DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications	11
Mapping cysteine ligandability	11
Repurposing beta-blockers in breast cancer	10
RNF41 reverses liver fibrosis	10
Roche buys MASH contender for up to US$3.5 billion	10
Top product forecasts for 2026	10
The potential of innovative trial design for efficiently evaluating repurposed drugs	10
BacPROTAC to treat tuberculosis	10
Boosting CAR T cell efficacy	10
Targeting ephrin signalling in sepsis	10
Chromatin-targeted drug discovery at “a very special moment”	10
Developing an IKZF2 glue degrader	10
Understanding semaglutide action in the brain	10
In vivo CAR T purchase spree continues with Lilly deal worth up to US$7 billion	10
New therapeutic candidate for Chagas disease	9
AhR inhibition promotes axon regeneration	9
Trikines rewire STAT signalling	9
Opportunities for mitochondrial disease gene therapy	9
2022 FDA approval number dips: a COVID-19 hangover?	8
Lipid flippase inhibitor tackles drug-resistant fungi	8
Fibrosis: cross-organ biology and pathways to development of innovative drugs	8
Deuterium in drug discovery: progress, opportunities and challenges	8
Expanding HSCs without cytokines	8
New route to target RAS	8
How multispecific molecules are transforming pharmacotherapy	8
Novel drug targets in 2023	8
Targeting immunogenic cell stress and death for cancer therapy	8
Monoclonal antibody to treat fentanyl overdose	8
FDA approves BTK inhibitor for chronic hives	8
FDA approves PI3K inhibitor for a rare immune disorder	8
2023 FDA approvals	8
FDA approves second anti-amyloid antibody for Alzheimer disease	8
BCMA-targeted bispecific gets first green light, in the EU	8
Advances in the treatment of systemic lupus erythematosus	8